SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Mahamaya Lifesciences Ltd (544611)

Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating BSE: 544611 NSE: Pesticides & Agrochemicals | Small Cap | Mahamaya Lifescience Share Price

₹160.40 5.40 (3.48%)

As on 05-Jun'26 16:59

Mahamaya Lifesciences Ltd (544611)

Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating BSE: 544611 NSE: Pesticides & Agrochemicals | Small Cap | Mahamaya Lifescience Share Price

₹160.40 5.40 (3.48%)

As on 05-Jun'26 16:59

Key Metrics
Valuation Multiples
Market Cap
₹375 Cr.
Current Price
₹160.4
52-Week Low / High
₹111 / 205
TTM EPS
₹7.1
TTM Sales
₹329 Cr.
Book Value per Share
₹48.8
P/E Ratio
22.45
Lower than its 5-year historical median
Industry PE
31.6
Price to Book (P/B)
3.29
Lower than its 5-year historical median
Price to Sales (P/S)
1.14
Lower than its 5-year historical median
EV/EBITDA
12.47
Lower than its 5-year historical median
Dividend Yield
0.00%
Profitability Efficiency
Return on Equity (ROE)
34.17%
Outperforms industry median
Return on Capital Employed (ROCE)
26.00%
Outperforms industry median
Return on Assets (ROA)
8.51%
Operating Profit Margin
8.8%
Net Profit Margin
4.85%
Gross Profit Margin
7.2%
Growth Momentum
1-yr vs 3-yr growth
Sales Growth (1 Year)
Improving versus 3-year growth rate
63.49%
Operating Profit Growth (1 Year)
Improving versus 3-year growth rate
69.6%
Net Profit Growth (1 Year)
Improving versus 3-year growth rate
134.37%
Asset Quality
Promoter Holding
56.35%
Pledged shares (%) of Promoter's holding (%)
0.00%
Reserves
₹91 Cr.
Equity
₹23.4 Cr.
Face Value
₹10
All Time Low / High
₹111.00 / 205.05

Mahamaya Lifesciences stock performance

Key Ratios
mw4me loader

Check Before You Invest

Valuation

Somewhat Undervalued

Price Trend

Weak
Q.1 Is Mahamaya Lifesciences Ltd a good quality company?
Mahamaya Lifesciences Ltd is a weak quality company, based on a inconsistent multi-year financial track record.

This assessment is based on company’s performance on Revenue growth, ROCE, Equity and Assets, key margin ratios, cash conversion cycle, and debt to cash flow from operations and how it compares with its long term averages.

We have analysed the performance of the company on the following:

  • How has it performed on generating Profits?

    By checking its Revenue growth, Gross, Operating and Net Margins compared to its last 5-year median.

  • How efficiently has it utilized Capital?

    By checking its ROCE, ROA, ROE and its Cash Conversion Cycle.

  • How is it managing its Debt?

    By checking its Debt to Equity and Cash Flow from Operations.

How does Mahamaya Lifesciences Ltd performance compare with that of its Peers?
Q.1 Revenue growth of Mahamaya Lifesciences Ltd vs industry peers?
Mahamaya Lifesciences Ltd revenue CAGR is 43.22%, compared to the industry median CAGR of 4.98%, indicating faster growth and gaining its market share.
Q.1 Promoter shareholding and pledge status of Mahamaya Lifesciences Ltd?
Promoters hold 56.35% of the Mahamaya Lifesciences Ltd, with 0.00% of their stake pledged, indicating no pledge risk.
Q.1 Stock return of Mahamaya Lifesciences Ltd over the last decade?
Over the last - year(s), the stock has delivered a CAGR of N/A% based on the current price.

10 Year X-Ray :

Analysis of Financial Track Record (Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end)

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.

Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.
Mahamaya Lifesciences Ltd has not performed well majority of the past ten years indicating its past ten year financial track record is not good

Value Creation

Mar'22Mar'23Mar'24Mar'25TTM
ROCE % 16.5%20.6%21.8%26%-
Value Creation
Index
0.20.50.60.9-

Growth Parameters

Sales 89.9137162264329
Sales YoY Gr.-52.5%17.9%63.5%-
Adj EPS 233.76.97.1
YoY Gr.-47.1%24.7%83.2%-
BVPS (₹) 11.614.418.328.148.8
Adj Net
Profit
2.84.15.112.217
Cash Flow from Ops. 1.90.8-23.5-3.4-
Debt/CF from Ops. 10.130-2.3-17.3-

CAGR

9 Years 5 Years 3 Years 1 Years
Sales NANA43.2%63.5%
Adj EPS NANA49.8%83.2%
BVPSNANA34.1%53.1%
Share Price - - - -

Key Financial Parameters

Mar'22Mar'23Mar'24Mar'25TTM
Return on
Equity %
17.523.122.932.418.6
Op. Profit
Mgn %
7.37.18.58.8NAN
Net Profit
Mgn %
3.133.24.65.1
Debt to
Equity
1.21.22.21.2-
Working Cap
Days
01151561650
Cash Conv.
Cycle
030801000

Profit And Loss

(All Figures are in Crores.)
PARTICULARSMar'22Mar'23Mar'24Mar'25
Sales90137162264
Operating Expenses + 83128148241
Manufacturing Costs2238
Material Costs73116136219
Employee Cost 5535
Other Costs 4569
Operating Profit 791423
Operating Profit Margin (%) 7.3%6.7%8.4%8.8%
Other Income + 0013
Exceptional Items 0000
Interest 2367
Depreciation 1112
Profit Before Tax 45817
Tax 1124
Profit After Tax 34513
PAT Margin (%) 3.1%2.7%3.4%4.9%
Adjusted EPS (₹)2.02.74.07.2
Dividend Payout Ratio (%)0%0%0%0%

Valuation of Mahamaya Lifescience - Standalone

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

mw4me loader

Analyst's Notes

data not found
No data found!

Balance Sheet

(All Figures are in Crores.)
PARTICULARSMar'22Mar'23Mar'24Mar'25

Equity and Liabilities

Shareholders Fund + 16202550
Share Capital 11118
Reserves 15182432
Debt +18225255
Long Term Debt101096
Short Term Debt8124349
Minority Interest0000
Trade Payables17292355
Others Liabilities 681329
Total Liabilities 5678112189

Fixed Assets

Net Fixed Assets +18202126
Gross Block20232531
Accumulated Depreciation2345
CWIP 2234
Investments 0000
Inventories193551100
Trade Receivables9102848
Cash Equivalents 1134
Others Assets 71076
Total Assets 5678112189

Cash Flow

(All Figures are in Crores.)
PARTICULARSMar'22Mar'23Mar'24Mar'25
Cash Flow From Operating Activity + 21-23-3
PBT 45817
Adjustment 2478
Changes in Working Capital -3-7-37-27
Tax Paid -1-1-1-2
Cash Flow From Investing Activity + -3-3-1-4
Capex -1-3-1-5
Net Investments 0000
Others -3000
Cash Flow From Financing Activity + 23258
Net Proceeds from Shares 00014
Net Proceeds from Borrowing -11-2-2
Interest Paid -1-3-6-7
Dividend Paid 0000
Others 45323
Net Cash Flow 01-01

Financial Ratio

PARTICULARSMar'22Mar'23Mar'24Mar'25
Ratios
ROE (%)17.5420.8924.3734.17
ROCE (%)16.4720.6321.7726
Asset Turnover Ratio1.612.041.691.75
PAT to CFO Conversion(x)0.670.25-4.6-0.23
Working Capital Days
Receivable Days3724.8042.7053
Inventory Days75.6071.1096.90104.50
Payable Days82.8070.9068.7064.90

Management X-Ray

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged *0.000.000.00
* Pledged shares as % of Promoter's holding (%)

Top 5 Mutual Funds Holding

Last Visited Stocks

Announcements

Mahamaya Lifesciences Ltd FAQs

The current trading price of Mahamaya Lifescience on 05-Jun-2026 16:59 is ₹160.4.

Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 04-Jun-2026 the market cap of Mahamaya Lifescience stood at ₹375.4 Cr

The latest P/E ratio of Mahamaya Lifescience as of 04-Jun-2026 is 22.45.

The latest P/B ratio of Mahamaya Lifescience as of 04-Jun-2026 is 3.29.

The 52-week high of Mahamaya Lifescience is ₹205.1 and the 52-week low is ₹111.0.

The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Mahamaya Lifescience is ₹329 ( Cr.) .

Past 10 year’s financial track record analysis by Moneyworks4me indicates that Mahamaya Lifesciences Ltd is a below average quality company.

The key valuation ratios of Mahamaya Lifesciences Ltd's currently when compared to its past seem to suggest it is in the Somewhat Undervalued zone.

The Price Trend analysis by MoneyWorks4Me indicates it is Weak which suggest that the price of Mahamaya Lifesciences Ltd is likely to Fall in the short term. However, please check the rating on Quality and Valuation before investing.

About Mahamaya Lifesciences Ltd

Mahamaya Lifesciences was originally incorporated as a private limited Company under the name of ‘Mahamaya Life Sciences Private Limited’ on May 07, 2002. Further, the company name was changed from ‘Mahamaya Life Sciences Private Limited’ to ‘Mahamaya Lifesciences Private Limited’ and a fresh certificate of Incorporation dated February 15, 2016 was issued by the Registrar of Companies, Delhi. Moreover, a special resolution was passed at the Extra-Ordinary General Meeting of the company held on October 29, 2024 for conversion of the company into a public limited company and the name of the company was changed from ‘Mahamaya Lifesciences Private Limited’ to ‘Mahamaya Lifesciences Limited’ on November 19, 2024.

The company specializes in the manufacturing of pesticide formulations and supply bulk formulations catering to both Indian agrochemical companies, as well as multinational corporations (MNCs). It began its journey by focusing on import and registration of vital pesticide molecules (Technical) that were not produced domestically in India. It imported these molecules after lot of product research and worked on registering them with the Central Insecticides Board and Registration Committee (CIBRC) under the Department of Agriculture, Government of India. After successful registration it marketed these molecules both as technical and as value added end use formulations for both domestic manufacturers and MNCs. 

The company, backed by over three decades of experience from its promoters, and senior managerial personnel possesses a deep understanding of both Technical and formulation supplies, which are essential to the pesticide industry. It specialises in safer environment friendly products. With its research and development capabilities, it identifies the latest, safer molecules, conducts field trials at State Agricultural Universities and carries out toxicology and chemistry studies at CIBRC approved laboratories. It invests in registration of new molecules, which are, once approved and registered are distributed within India. With an advanced formulation plant, the company supplies products across the country and has marketing agreements with multinationals corporations.

Leveraging the extensive experience of its promoter and managing director Krishnamurthy Ganesan, in the agrochemical industry, it has played a key role in shaping its expertise in identifying high-growth products, securing their registration with the CIBRC, and conducting comprehensive Research & Development. Its emphasis is on cultivating strong relationship with both domestic companies and multinational corporations. It is focused on developing and expanding biological crop care products including bio stimulant formulations, plant growth regulators, bio fertilizers, as well as new age bio-fermented insecticides, fungicides and herbicides all designed to be low in toxicity and eco-friendly.

The sales of its branded products across various states are managed by its experienced sales team, who have extensive product knowledge and market expertise. Each state is supported by a dealer network, ensuring the brand's business is handled effectively and efficiently, with a strong focus on meeting customer needs and maintaining consistent product availability. Its branded products are dispatched from its factory to warehouses/godowns in various states, and subsequently distributed to dealers, who sell them to farmers.

Business area of the company

The company specializes in the manufacturing of pesticide formulations and supply bulk formulations catering to both Indian agrochemical companies, as well as multinational corporations (MNCs). It began its journey by focusing on import and registration of vital pesticide molecules (Technical) that were not produced domestically in India. It imported these molecules after lot of product research and worked on registering them with the Central Insecticides Board and Registration Committee (CIBRC) under the Department of Agriculture, Government of India. After successful registration it marketed these molecules both as technical and as value added end use formulations for both domestic manufacturers and MNCs.

Products categories of the company

  • Bulk Formulations Sales 
  • Technical Sales 
  • Brand Sales (own brand product) 
  • Exports- Formulations

Awards and recognitions

  • 2023: One of the top 10 Pesticides and Insecticides Manufacturers

History and millstones

  • 2002: Incorporation of the Company in the name and style of ‘Mahamaya Life Sciences Private Limited’ under Companies Act, 1956.
  • 2016: Company name was changed from ‘Mahamaya Life Sciences Private Limited’ to ‘Mahamaya Lifesciences Private Limited’.
  • 2018: The Company received CTE from the Gujarat Pollution Control Board, and then began construction of factory in Dahej, Gujarat.
  • 2021: The factory plant was completed and after obtaining License to Manufacture Insecticides from Directorate of Agriculture, Government of Gujarat, formulations of insecticide were started in the factory.
  • 2024: Conversion of the Company from private limited to public limited.

You have 2 views remaining as a Guest User. To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login Now

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×